Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  For the Patient  |  Careers at Hemispherx  


Research and Development
Drug Candidates
Patent Portfolio
Clinical Development
Clinical Trial Information
Professional Services
Educational Resources

 

Selected Peer Review Publications

Eur J Clin Microbiol Infect Dis. 1996 Jul; 15(7):580-7

Results of a double-blind placebo-controlled study of the double-stranded RNA drug Poly(I):PolyC12U in the treatment of HIV infection.

 

Thompson KA, Strayer DR, Salvato PD, Thompson CE, Klimas N, Molavi A, Hamill AK, Zheng Z, Ventura D, Carter WA.

Abstract available on Med Pub

National Library of Medicine:

http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=97027989&Dopt=b&tool=rware

 
 

In Vivo. 1994 May-Jun; 8(3):375-81

Synergistic inhibition of AZT-resistant HIV by AZT combined with Poly(I):PolyC12U, without synergistic toxicity to bone marrow progenitor cell elements.

 

 

Gillespie D, Hubbell HR, Carter WA, Midgette P, Elsasser W, Mullaney R, Strayer DR.

 

Abstract available on Med Pub

National Library of Medicine:

http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=95101981&Dopt=b&tool=rware

 

Clin Infect Dis 1994 Jan;18 Suppl 1:S88-95

A controlled clinical trial with a specifically configured RNA drug, Poly(I):Poly(C12U), in Chronic Fatigue Syndrome

 

Strayer DR, Carter WA, Brodsky I, Cheney P, Peterson D, Salvato P, Thompson C, Loveless M, Shapiro DE, Elsasser W, et al.


Abstract available:

AMP 502


 

Vanderbilt School of Medicine, San Juan, Puerto Rico, 2000 Dec
Poly(I): Poly(C12U) Produces a Sustained Reduction in HIV Load

Strayer, D.R., Carter, W.A., Khutoryansky, N., Mitchell, W.M.


Am J Med 2000 Feb; 108: 99-105
A 37kDa 2-5A Binding Protein as a Potential Biochemical Marker for Chronic Fatigue Syndrome

Kenny De Meirleir, MD., PhD, Catherine Bisbal, PhD, Isabelle Campine, MD, Pascale De Becker, PT, Tamin Salehzada, PhD., Edith Demettre, MSc, Bernard Lebleu, PhD

 

Presented at Major Drug Development in Antiretroviral Research (DART) Conference 2002, Naples, FL, December 17, 2002
 
A Phase IIB Prospective, Randomized, Controlled Study Evaluating the Immunomodulatory Role of Poly I:Poly C12U  Against HIV During Structured Treatment Interruption (STI) of HAART
 
D. Strayera, G. Blickb, W. Mitchella,c W. Cartera and AMP 720 Investigators* Hemispherx Biopharmaa, Philadelphia PA; Circle Medicalb, Norwalk, CT; Vanderbilt Universityc, Nashville, TN
 

 
Information contained on the Hemispherx website other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed on the Hemispherx website and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this website. The Company disclaims, however, any intent or obligation to update these forward-looking statements.